From a small pharmaceutical factory in Lianyungang producing mercurochrome and gentian violet in 1970, to an IPO on the Hong Kong Stock Exchange in 2025 raising HK$11.4 billion—the largest fundraising in the pharmaceutical sector over the past five years; from being stereotyped prior to 2014 as a “generic drug-focused” company, to having innovative drug sales account for over 60% of total pharmaceutical sales in Q1 2026—Hengrui Medicine’s transformation epitomizes China’s pharmaceutical industry’s evolution from “lagging behind” to “running alongside” global leaders.
Combining generic drug development with innovation, Hengrui has entered the ranks of First-in-Class developers.
Yin Hang, Head of Hengrui Medicine’s Oncology Business Unit, summarized his nearly one-year experience at Hengrui as “three impressions.”
The first impression concerns history. At No. 145 Renmin East Road in Lianyungang stands a modest four-story building constructed in the 1980s—the place where Hengrui’s dream began. In 1970, Hengrui’s predecessor, the Lianyungang Pharmaceutical Factory, produced only mercurochrome and gentian violet. In 1987, the company successfully developed its first anti-cancer drug, etoposide. In 2000, it was listed on the Shanghai Stock Exchange. In 2002, the Shanghai Hengrui R&D Center was established, marking the beginning of its innovation-driven transformation.
The second impression relates to structure. China’s oncology market recorded a compound annual growth rate (CAGR) of 16% between 2020 and 2025. At Hengrui, growth in oncology innovative drugs has been even more robust: by 2025, revenue from oncology innovative drugs accounted for 80% of the company’s total innovative drug revenue. Yin Hang remarked, “We hope people will revise one misconception: although Hengrui began with generic drugs, Hengrui today is fundamentally an innovative pharmaceutical company.”
The third impression centers on the National Medical Insurance Negotiations. During the 2025 negotiations, the Hengrui team reported daily at 8:30 a.m. and departed at 6:30 p.m., fully participating for three consecutive days. Recalling the final negotiation session, Yin Hang noted that the experts had grown familiar with the team: “When we walked in, they said, ‘Ah, you’re from Hengrui—we recognize you! How many products have you negotiated?” Meanwhile, upon reviewing the list of products under negotiation, the insurance negotiation experts expressed awe: “We truly hadn’t expected Chinese innovation to have advanced to this level.”
Today, Hengrui has 21 Class 1 innovative drugs and 4 Class 2 new drugs included in the National Reimbursement Drug List (NRDL). In 2026, the company obtained approval for Rilafusp‑α, a first-in-class PD‑L1/TGF‑β bispecific antibody—the first to successfully target both pathways. Its HER2‑directed ADC, Ruikang trastuzumab, achieved a median progression‑free survival of 30.6 months in breast cancer, while the CDK4/6 inhibitor dalpiciclib reduced postoperative recurrence risk by 40%.
In cardiovascular and metabolic disease, Hengrui is developing Ruippotatide, a GLP‑1/GIP dual agonist with a GLP‑1‑dominant profile and a 15‑amino‑acid sequence difference from tirzepatide, designed to balance metabolic benefit with tolerability. In 2024, Hengrui out‑licensed rights to Ruippotatide and two other GLP‑1 assets for territories outside Greater China to U.S.‑based Kailera Therapeutics, in a deal worth up to USD 6 billion in upfront and milestone payments, plus an equity stake in Kailera. Kailera went public on Nasdaq in April 2026 in one of the largest biotech IPOs to date.
Medical Insurance Policies Safeguard the High-Quality Development of Innovative Drugs
Since its establishment in 2018, China’s National Healthcare Security Administration (NHSA) has implemented systematic reforms—including dynamic NRDL adjustments, centralized procurement, and value‑based assessment—that have shortened the timeline from drug approval to reimbursement. Approximately 80% of innovative drugs now secure NRDL inclusion within two years of approval.
Hengrui President Feng Ji noted that the NHSA’s policies bridge two priorities: ensuring patient access to essential medicines and supporting the industry’s transition toward high‑value innovation. A company representative added that drug regulatory reform and medical insurance reform have served as dual pillars—the former clearing the path for new drug approvals, the latter establishing a predictable commercial return pathway for innovators.
To date, Hengrui has invested over RMB 55 billion in R&D, maintaining R&D spending at over 25% of revenue for consecutive years—among the highest in China’s pharmaceutical sector. The company operates 15 R&D centers across Asia, Europe, and Australia, with a global R&D team of more than 5,600. It has 26 Class 1 innovative drugs and 6 Class 2 new drugs approved in China, with over 100 proprietary products in clinical development and more than 400 clinical trials underway globally.
Beyond basic medical insurance, commercial health insurance also serves as a critical pillar for financing innovative drugs. By the end of 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security jointly issued the “National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalogue (2025 Edition)” and the inaugural “Commercial Health Insurance Innovative Drug Catalogue (2025 Edition),” which clarified the “three exclusions” policy for innovative drugs covered under commercial health insurance: (1) drugs listed in the commercial health insurance innovative drug catalogue are excluded from hospitals’ basic medical insurance self-payment rate indicators; (2) such drugs are excluded from monitoring of substitutable products within centralized procurement programs; and (3) cases involving drugs covered under relevant commercial health insurance plans may be excluded from Diagnosis-Related Groups (DRG) or Disease-Severity Based Payment (DIP) schemes upon review and evaluation.
This suite of policies facilitates the rapid inclusion of China-developed innovative drugs in hospitals via commercial health insurance products, thereby enhancing patient access to these medications.
Made in China, Used Globally
Beyond hospital-based clinical trials, Real-World Studies (RWS) are emerging as another critical pathway for validation. The National Healthcare Security Administration (NHSA) has established a standardized, comprehensive real-world evaluation system for healthcare insurance value. To date, it has built a trusted evaluation network comprising 79 inaugural institutions and issued the “Guidelines for Comprehensive Real-World Insurance Value Evaluation of Pharmaceuticals (Trial Version),” offering clear direction to enterprises conducting clinical research and substantiating drug value. Hengrui Medicine has initiated over 70 real-world studies and, guided by these technical standards, is actively exploring high-quality clinical evidence to support scientifically informed decision-making by health insurance authorities.
For pharmaceutical companies, gaining inclusion in the national health insurance reimbursement list is merely the first step; the second—and equally vital—step is executing robust real-world studies, which facilitate stronger global expansion.
According to a senior Hengrui executive, large-scale clinical data and real-world evidence generated from clinical trials conducted on China’s vast patient population constitute a unique competitive advantage for Chinese innovative drugs in the global arena. High-quality clinical evidence derived from extensive patient use not only supports insurance renewal negotiations and innovation-driven R&D but also serves as pivotal leverage in overseas regulatory submissions and international business development (BD) negotiations.
“Going global” is currently Hengrui’s strategic priority. Following its 2025 listing on the Hong Kong Stock Exchange, Hengrui completed 13 outbound licensing deals within three years, with potential total transaction value approaching USD 42 billion. Its partners include global pharmaceutical giants such as Merck & Co. (MSD), GlaxoSmithKline (GSK), and Bristol Myers Squibb (BMS). The collaboration with BMS is particularly distinctive: not only does Hengrui license assets to BMS, but BMS also entrusts select early-stage projects to Hengrui. Moreover, Hengrui holds an option to co-develop specific programs and may jointly commercialize designated products with BMS on a global scale.
Whether expanding overseas or scaling domestically, the fundamental prerequisite is that innovative medicines truly reach patients. Yin Hang shared a story that left a lasting impression: At the China International Import Expo (CIIE) prior to the 2021 national health insurance negotiation, a cancer patient under age 40 circled Hengrui’s exhibition booth for over an hour before finally approaching and saying, “Wishing you good luck in the health insurance negotiation.”
Days later, this innovative oncology drug was successfully included in the National Reimbursement Drug List (NRDL)—a moment of exhilaration still vivid in Yin Hang’s memory. He knows full well how long countless cancer patients had awaited this milestone. Today, carrying forward this unwavering commitment to patient care, Yin Hang has embarked on a new journey at Hengrui Medicine—a company boasting a rich pipeline of innovative candidates—dedicated to delivering high-quality, homegrown innovative medicines to more patients worldwide.
From Lianyungang to the globe, from generic drugs to first-in-class therapies, from “accessibility” to “optimal use,” Hengrui’s 55-year evolution mirrors the broader trajectory of China’s innovative pharmaceutical industry. The true value of an innovative drug extends far beyond whether its molecule can be designed, its data published, or its price negotiated—it ultimately manifests in whether physicians can prescribe it through electronic health record systems and whether patients can actually access and benefit from it.
To transform “Made in China” into “Used Globally,” and to advance from “accessibility” to “optimal use”—that is the most solemn and meaningful response to the patient’s heartfelt wish: “Wishing you good luck.”